APA (7th ed.) Citation

LL, R., M, L., CD, E., JA, Z., J, S., EC, C., . . . MA, M. (2026). Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial. Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(6), e71577. https://doi.org/10.1002/alz.71577

Chicago Style (17th ed.) Citation

LL, Raket, et al. "Donanemab Treatment Effect by Baseline Tau Burden and Disease Severity: Observations from the TRAILBLAZER-ALZ 2 Trial." Alzheimer's & Dementia : The Journal of the Alzheimer's Association 22, no. 6 (2026): e71577. https://doi.org/10.1002/alz.71577.

MLA (9th ed.) Citation

LL, Raket, et al. "Donanemab Treatment Effect by Baseline Tau Burden and Disease Severity: Observations from the TRAILBLAZER-ALZ 2 Trial." Alzheimer's & Dementia : The Journal of the Alzheimer's Association, vol. 22, no. 6, 2026, p. e71577, https://doi.org/10.1002/alz.71577.